Search Results

You are looking at 81 - 90 of 137 items for :

  • "febrile neutropenia" x
  • Refine by Access: All x
Clear All
Full access

Amy A. Kirkham, Karen A. Gelmon, Cheri L. Van Patten, Kelcey A. Bland, Holly Wollmann, Donald C. McKenzie, Taryne Landry, and Kristin L. Campbell

: implication and proposed mechanisms . World J Clin Oncol 2014 ; 5 : 272 – 282 . 10.5306/wjco.v5.i3.272 25114844 23. Kuderer NM , Dale DC , Crawford J , . Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients

Full access

David S. Ettinger, Douglas E. Wood, Dara L. Aisner, Wallace Akerley, Jessica R. Bauman, Ankit Bharat, Debora S. Bruno, Joe Y. Chang, Lucian R. Chirieac, Malcolm DeCamp, Thomas J. Dilling, Jonathan Dowell, Gregory A. Durm, Scott Gettinger, Travis E. Grotz, Matthew A. Gubens, Aparna Hegde, Rudy P. Lackner, Michael Lanuti, Jules Lin, Billy W. Loo Jr, Christine M. Lovly, Fabien Maldonado, Erminia Massarelli, Daniel Morgensztern, Thomas Ng, Gregory A. Otterson, Sandip P. Patel, Tejas Patil, Patricio M. Polanco, Gregory J. Riely, Jonathan Riess, Steven E. Schild, Theresa A. Shapiro, Aditi P. Singh, James Stevenson, Alda Tam, Tawee Tanvetyanon, Jane Yanagawa, Stephen C. Yang, Edwin Yau, Kristina M. Gregory, and Miranda Hughes

were not predictive of survival. Grade 3 or worse treatment-related adverse events were reported in 30% (14/46) of patients; the most common events were increased lipase and febrile neutropenia (7% [3/46] for both). 22 None of the adverse events were

Full access

Adam J. Olszewski, Kalyan C. Mantripragada, and Jorge J. Castillo

%), red blood cell transfusions (47%), and arrhythmias (4%). Similarly, Delarue et al 4 found an 18% rate of febrile neutropenia and a 4% rate of cardiovascular severe adverse effects, with 13% of all fatalities ascribed to complications of R-CHOP. The

Full access

Suzanne C. O'Neill, Claudine Isaacs, Calvin Chao, Huei-Ting Tsai, Chunfu Liu, Bola F. Ekezue, Nandini Selvam, Larry G. Kessler, Marc D. Schwartz, Tania Lobo, and Arnold L. Potosky

. 38. Chia VM Page JH Rodriguez R . Chronic comorbid conditions associated with risk of febrile neutropenia in breast cancer patients treated with chemotherapy . Breast Cancer Res Treat 2013 ; 138 : 621 – 631 . 39. Hall PS McCabe C

Full access

Maxim Norkin and John R. Wingard

febrile neutropenia alone if they are receiving Candida prophylaxis, lack biomarker positivity, and have no clinical signs or imaging abnormalities suggestive of IFI. 13 However, any high-risk patient with a nodular pulmonary infiltrate should be

Full access

Pamala A. Pawloski, Gabriel A. Brooks, Matthew E. Nielsen, and Barbara A. Olson-Bullis

-stimulating factor use without an increase in febrile neutropenia rates, illustrating the positive impact these powerful tools can have on clinical oncology care. 50 Further analyses of the use of these tools with appropriate study designs and analytic methods are

Full access

P. Connor Johnson, Caron Jacobson, Alisha Yi, Anna Saucier, Tejaswini M. Dhawale, Ashley Nelson, Mitchell W. Lavoie, Mathew J. Reynolds, Carlisle E.W. Topping, Matthew J. Frigault, and Areej El-Jawahri

determine reasons for hospital readmissions. 12 In the schema for our study, these reasons included symptoms, fever without a source, febrile neutropenia, confirmed infection, dehydration/electrolyte abnormalities, planned hospitalization

Full access

William G. Wierda, John C. Byrd, Jeremy S. Abramson, Syed F. Bilgrami, Greg Bociek, Danielle Brander, Jennifer Brown, Asher A. Chanan-Khan, Julio C. Chavez, Steve E. Coutre, Randall S. Davis, Christopher D. Fletcher, Brian Hill, Brad S. Kahl, Manali Kamdar, Lawrence D. Kaplan, Nadia Khan, Thomas J. Kipps, Megan S. Lim, Shuo Ma, Sami Malek, Anthony Mato, Claudio Mosse, Mazyar Shadman, Tanya Siddiqi, Deborah Stephens, Suchitra Sundaram, Nina Wagner, Mary Dwyer, and Hema Sundar

arms (86% and 85% for ibrutinib + obinutuzumab and chlorambucil + obinutuzumab, respectively). Pneumonia (5%), atrial fibrillation (4%), febrile neutropenia (4%), and pyrexia (4%) were the most common adverse events in the ibrutinib + obinutuzumab arm

Full access

Robert W. Carlson, Susan Moench, Arti Hurria, Lodovico Balducci, Harold J. Burstein, Lori J. Goldstein, William J. Gradishar, Kevin S. Hughes, Mohammad Jahanzeb, Stuart M. Lichtman, Lawrence B. Marks, Joan S. McClure, Beryl McCormick, Lisle M. Nabell, Lori J. Pierce, Mary Lou Smith, Neal S. Topham, Tiffany A. Traina, John H. Ward, and Eric P. Winer

prophylaxis with granulocyte-colony stimulating factors (G-CSF) versus placebo or untreated controls in patients undergoing chemotherapy indicated that G-CSF therapy was associated with decreased incidences of febrile neutropenia and early death, and a higher

Full access

Pamela S. Becker

-filgrastim is indicated to reduce the duration of severe neutropenia in patients with nonmyeloid malignancies receiving myelosuppressive chemotherapy drugs associated with a clinically significant incidence of febrile neutropenia. Tbo-filgrastim is approved as a